Nexentis Technologies Inc. (NXTS) AI Stock Analysis
NXTS AI stock analysis summary
AI ResearchNexentis Technologies Inc. (NXTS) develops therapeutics for cancer and metabolic diseases alongside renewable energy projects. Over the trailing twelve months, the company generated $209,000 in revenue with an EPS of -$21.55. Although it holds a net cash balance of $8.5M as of June 30, 2026, its 1-year stock return declined 97.7%.
- Market cap
- $937,545
- Revenue (TTM)
- $209,000
- P/E
- —
- 1Y return
- -97.7% S&P 500 16.8%
- Avg. target
- —
Bull case
- The company maintains a solid liquidity cushion with $8.9M in cash and short-term investments against just $426,000 in total debt as of June 30, 2026.
- Nexentis holds a favorable liquidity profile demonstrated by a current ratio of 3.72.
- Insiders retain meaningful alignment with external shareholders, holding 21.2% of total shares.
Bear case
- The stock has lost substantial market value, with a 1-year return of -97.7% compared to a 16.8% gain for the S&P 500.
- Revenue in the latest quarter ending June 30, 2026, contracted by 77.8% year-over-year, reaching just $209,000 over the trailing twelve months.
- The company continues to burn cash, posting a free cash flow of -$3.4M and a net loss of -$5.2M in FY2024.
What Nexentis Technologies does
Nexentis Technologies Inc., formerly known as N2OFF, Inc., is based in Ness Ziona, Israel, and operates through two segments: Biotechnology Activity and Renewable Energy Projects. Through its subsidiary, the company develops therapeutics focused on cancer and inflammatory metabolic diseases. Its pipeline includes MITOLINE, an algorithm designed to perform multiple sequence and structure pairwise alignments for generating 3D comparative models of mitochondrial carrier proteins. Additionally, Nexentis develops a cloud-based computational chemistry platform, novel in-vitro screening platforms, and advanced 3D NSCLC tumor spheroid systems.
Growth and profitability
Nexentis Technologies experienced revenue contraction in recent fiscal years, falling from $438,141 in FY2021 to $394,004 in FY2022, $263,445 in FY2023, and $210,000 in FY2024. Revenue growth was -20.3% in FY2024, alongside a gross margin of 15.7% and an operating margin of -1928.1%. Net loss was -$5.2M in FY2024, representing an improvement from -$6.5M in FY2023. For the trailing twelve months ended June 30, 2026, revenue stood at $209,000, while quarterly revenue growth fell 77.8% year-over-year. Research and development expenses were $367,000 in FY2024, down from $1.9M in FY2023.
Balance sheet and cash flow
As of June 30, 2026, Nexentis reported cash and short-term investments of $8.9M against total debt of $426,000, resulting in a net cash position of $8.5M. Total assets stood at $18.7M, while shareholders' equity was $1.9M. The company maintains a current ratio of 3.72 and a debt-to-equity ratio of 0.22. Free cash flow in FY2024 was -$3.4M, matching operating cash flow of -$3.4M, with FY2025 capital expenditures recorded at $14,000.
Valuation and performance
Nexentis Technologies trades at a price-to-sales multiple of 4.3x and an enterprise value to EBITDA ratio of 0.3x, supported by a market capitalization of $937,545 and an enterprise value of -$6.2M. In comparison, the median of its US-listed Basic Materials peers reflects a price-to-sales multiple of 1.8x and an EV to EBITDA ratio of 10.5x. Over the past year, NXTS recorded a return of -97.7%, significantly trailing the S&P 500 benchmark return of 16.8%.
What analysts expect
Nexentis Technologies has its next earnings announcement scheduled for November 12, 2026. Market coverage lacks published Wall Street consensus ratings or price targets following its recent close at $0.65. Insider ownership stands at 21.2%, while institutional holdings account for 4.4% of total shares. Short interest represents 2.8% of the float. With trailing twelve month diluted EPS at -$21.55, future financial releases will provide insight into ongoing biotechnology pipeline developments.
Key risks and what to watch
- Substantial dilution risk exists given the 6996.5% increase in 5-year share count.
- The enterprise exhibits elevated price volatility, evidenced by a high beta of 1.86.
- Persistent operating deficits remain a risk, as evidenced by an operating margin of -1928.1% in FY2024.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this NXTS AI stock analysis
This page is an AI-written research summary of Nexentis Technologies Inc. (NXTS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: NXTS income statement, NXTS balance sheet, NXTS key metrics, NXTS chart. See the NXTS stock overview for the latest quote and news.
NXTS AI stock analysis FAQ
What is the market capitalization of Nexentis Technologies?
Nexentis Technologies has a market capitalization of $937,545 as of October 16, 2026.
When is the next earnings release date for NXTS?
The next earnings date for Nexentis Technologies is scheduled for November 12, 2026.
Does Nexentis Technologies pay a dividend?
Nexentis Technologies does not pay a regular dividend.
How much cash and debt does Nexentis hold?
As of June 30, 2026, the company held $8.9M in cash and short-term investments alongside $426,000 in total debt, yielding net cash of $8.5M.